Scarica l'app Stockscreener
9.255
1.68%
0.125
Zevra Therapeutics Inc Borsa (ZVRA) Ultime notizie
Nio, Zevra Therapeutics, Vertex Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
How (ZVRA) Movements Inform Risk Allocation Models - Stock Traders Daily
Hypersomnia Pipeline Advances with 3+ Companies Developing Innovative Therapies and Expanding Clinical Research | DelveInsight - Barchart
Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT - MSN
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer under Nasdaq Listing Rule 5635(4) - marketscreener.com
Zevra shares jump after selling SDX portfolio for $50M - MSN
ZVRA Stock Price, Quote & Chart | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
Zevra Ties NPC Testing Push To Valuation Gap And New CFO - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Published on: 2026-03-21 14:23:45 - baoquankhu1.vn
Assessing Zevra Therapeutics (ZVRA) Valuation After Recent Share Price Moves And Rare Disease Milestone - Sahm
New Zevra finance chief gets a 300,000-share stock option - Stock Titan
GeneDx (WGS), Zevra Therapeutics (ZVRA) partner to launch sponsored genetic testing program for NPC - MSN
GeneDx (WGS), Zevra Therapeutics (ZVRA) Partner to Launch Sponsored Genetic Testing Program for NPC - Yahoo Finance
Zevra Therapeutics announced that, in accordance with Nasdaq Listing Rule 5635(C)(4), it has granted an inducement equity award to the company's new Chief Financial Officer. - Bitget
CFO at Zevra (NASDAQ: ZVRA) receives 300,000-share option grant - Stock Titan
Zevra Therapeutics (ZVRA) CFO Justin Renz files insider ownership report - Stock Titan
Zevra Therapeutics appoints Justin Renz as CFO - MSN
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewswire Inc.
BTIG initiates Zevra Therapeutics stock with buy on Miplyffa outlook - Investing.com Nigeria
R. LaDuane Clifton (ZVRA) files Form 144 showing 11,000‑ and 3,000‑share sales - Stock Titan
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million and Settles Delaware Lawsuit 1 - Minichart
Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap UpStill a Buy? - MarketBeat
Zevra Therapeutics Agrees to Sell SDX Portfolio to Commave Therapeutics for $50 Million - marketscreener.com
Zevra Shares Jump After Selling SDX Portfolio For $50M - Benzinga
Zevra Therapeutics, Inc.Common Stock (NQ: ZVRA - The Chronicle-Journal
BTIG initiates Zevra Therapeutics stock with buy on Miplyffa outlook By Investing.com - Investing.com Australia
Zevra Therapeutics (NASDAQ:ZVRA) Now Covered by BTIG Research - MarketBeat
Zevra Therapeutics (ZVRA) Sells Serdexmethylphenidate Portfolio to Commave for $50 Million - GuruFocus
Zevra Sells SDX Portfolio and Resolves Litigation - TipRanks
Zevra Therapeutics, Inc. $ZVRA Shares Bought by Kingdon Capital Management L.L.C. - MarketBeat
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million - Quiver Quantitative
Zevra Therapeutics Sells Sdx Portfolio To Commave Therapeutics For $50 Million - TradingView
Zevra Sells SDX Portfolio to Commave for $50 Million, Ends Azstarys Pact and Repays Credit Facility - TradingView
ZVRA: BTIG Initiates Coverage with a "Buy" Rating and $23.00 PT - GuruFocus
Zevra (Nasdaq: ZVRA) sells SDX portfolio for $50M and repays $63M loan - Stock Titan
Zevra jumps 19% after Q4 EPS tops consensus estimates - MSN
A Look At Zevra Therapeutics (ZVRA) Valuation After Profitability And MIPLYFFA Commercial Progress - Sahm
Zevra Therapeutics (NASDAQ:ZVRA) Cut to "Hold" at Wall Street Zen - MarketBeat
Aug Macro: Is Zevra Therapeutics Inc backed by strong institutional buying2026 Key Highlights & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Trading Systems Reacting to (ZVRA) Volatility - Stock Traders Daily
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR) - The Globe and Mail
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today - AOL.com
Analysts Set Expectations for ZVRA Q1 Earnings - MarketBeat
Zevra Therapeutics Faces Partnership Hurdles That Could Delay Drug Development and Pressure Financing - The Globe and Mail
Zevra Therapeutics Inc (ZVRA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Driven by MIPLYFFA Sales - GuruFocus
Trading Action: Should I set a stop loss on Zevra Therapeutics IncEarnings Beat & Daily Profit Focused Screening - baoquankhu1.vn
Is Zevra Therapeutics (ZVRA) Pricing Reflecting Its Strong Multi‑Year Share Price Performance - Yahoo Finance
WGS, Zevra Partner to Launch Genetic Testing for Niemann-Pick Type C - Zacks Investment Research
Zevra at Citizens Life Sciences: Strategic Growth and Expansion By Investing.com - Investing.com Canada
Zevra Therapeutics (NASDAQ:ZVRA) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
ZVRA: MIPLYFFA drives rare disease growth with strong revenue, global expansion, and pipeline progress - TradingView
Can Zevra Therapeutics (ZVRA) Turn NPC Genetic Testing Access Into a Durable Rare-Disease Edge? - Yahoo Finance
Zevra Therapeutics (ZVRA) Gets a Buy from Roth MKM - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Zevra Therapeutics (ZVRA) and Cooper Co (COO) - The Globe and Mail
Brokers Offer Predictions for ZVRA Q3 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Jazz Pharmaceuticals (JAZZ) and Talkspace (TALK) - The Globe and Mail
0.99%
3.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):